MCO
PTCT icon

MAK Capital One’s PTC Therapeutics PTCT Stock Holding History

MAK Capital One’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-221,723
Closed -$10.4M – 8
2018
Q3 		$10.4M Sell
221,723
-72,295
-25% -$2.99M 3.41% 3
2018
Q2 		$9.92M Buy
294,018
+22,006
+8% +$686K 1.69% 4
2018
Q1 		$7.36M Buy
+272,012
New +$6.89M 9.24% 3

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

MAK Capital One's PTCT Position: Q4 2018 in Review

MAK Capital One sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 221,723 shares — an estimated $10.4M sold.

MAK Capital One first reported a position in PTCT in Q1 2018 and held it in 3 quarters. The position peaked at $10.4M in Q3 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • MAK Capital One reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • MAK Capital One sold 221,723 PTC Therapeutics shares in Q4 2018, an estimated $10.4M.
  • MAK Capital One first reported a position in PTC Therapeutics in Q1 2018 and held it in 3 quarters.
  • MAK Capital One's PTC Therapeutics position peaked at $10.4M in Q3 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on MAK Capital One's 13F filing for Q4 2018, filed 14 Feb 2019.